Q&A With New Medical Expert: Dr. Jack Bleesing, MD, PhD
Medpace is proud to welcome Dr. Jack Bleesing, an accomplished immunologist and board-certified physician-scientist, with 20+ years of experience to...
JSMO 2025 HighlightsÂ
As biopharmaceutical companies seek to optimize clinical trial design, accelerate regulatory approvals, and improve patient outcomes, insights from JSMO 2025 provide a critical foundation for…
Oncology Breakthroughs – ESMO Congress 2024
Upon their return from ESMO Congress 2024 and in recognition of World Cancer Research Day, Medpace oncology experts identified three...
Oncology Breakthroughs – ASCO 2024 Highlights
Explore insights from Medpace oncology experts as they identify several of the latest innovations in hematologic and oncologic research shared at ASCO 2024.
4 Key Considerations for Designing Immuno-Oncology Trials
As more agents approach the clinic, it is imperative for researchers to consider the design and conduct of immuno-oncology clinical trials. Given the diversity of…
The Current Biomarker Landscape in Immuno-Oncology
Dr. El Mustapha Bahassi, Associate Director of Clinical Laboratories at Medpace, highlights the biomarker landscape in immuno-oncology clinical research.